1. ACC (Antibody-Cell Conjugation) technology
2. γδ2 T cell therapy
3. ACE1831
4. ACE2016
5. ACE1708

Challenges
Economic Losses:

The COVID-19 pandemic has caused significant economic losses exceeding 20 trillion USD globally.

Vaccine Hesitancy:

Despite the introduction of mRNA vaccines, vaccine hesitancy among the public continues to persist.

Evolvin

1. Novel Antibiotics: Positioned as second-line therapy, they are primarily used to treat infections associated with dialysis and joint replacement, and can be combined with existing lines of antibiotics as an adjuvant treatment.

2. Parkinson's Disease Drugs: Utilizing a novel and proprietary autophagy system-based targeted protein degradation drug technology platform, we seek pathways that can inhibit (delay) the degeneration of dopaminergic cells to develop therapeutic drugs, thereby alleviating the suffering caused by Parkinson's disease.

Streamline Bio Taiwan Corporation primarily provides AI-driven cell and gene therapy manufacturing automation platforms. Its core products include autonomous precision robotic systems, process control software, and integrated biomanufacturing workflow solutions. The platform automates operations such as cell culture, liquid handling, sample analysis, quality control testing, and process data acquisition. By leveraging closed-loop control and intelligent scheduling technologies, it enhances production efficiency and batch-to-batch consistency. The system seamlessly integrates with existing biomanufacturing equipment and GMP production environments. It is applicable to manufacturing workflows for CAR-T, cell therapy, gene therapy, and advanced therapy medicinal products (ATMPs), helping biotechnology companies reduce production costs, shorten technology transfer timelines, and accelerate the commercialization process.